Second Clinical Site Opened in Ph 1 Clinical Study of JBZ-001
“We are excited to add a second center to our first-in-human trial, serving the Mountain Region and allowing more geographical access to patients,” said Tamara Jovonovich, PhD, Chief Executive Officer of Jabez Biosciences. “We are currently enrolling our second dose cohort in the dose-escalation portion of the study. Opening the trial at a second site expands our reach and our hope of delivering best-in-class therapies that address the unmet needs of cancer patients. JBZ-001’s unique mechanism of action, which targets multiple pathways beyond nucleotide depletion, offers hope for a broad spectrum of oncological indications, and we are eager to see its potential unfold in this trial.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data